Sanofi Must Face Cancer Drug FCA Claims At Trial

Law360 (November 12, 2020, 10:09 PM EST) -- A Pennsylvania federal judge on Thursday handed drugmaker Sanofi U.S. Services Inc. a win on some allegations in a whistleblower's 18-year-old False Claims Act lawsuit, but allowed other claims that the drugmaker misleadingly promoted off-label uses for its cancer therapy drug to head to trial.

In a 51-page memo, U.S. District Judge Anita B. Brody trimmed claims accusing Sanofi predecessor Aventis Pharmaceuticals of engaging in false advertising and issuing kickbacks to physicians who promoted its cancer drug, Taxotere.

But Sanofi still faces former sales representative Yoash Gohil's claims that it orchestrated an advisory board scheme, a speaker programs scheme, an education...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!